Market Cap
$338.4M
EBS
Emergent BioSolutions Inc.
$6.26 ▼ -1.73%
Prev close $6.37Market cap$338.4M
ConsensusBuy
12-mo target$11.00 (+75.7%)
▲ Bullish
Analyst conviction 7/10
Insider Selling Cluster (4 insiders)High Impact Filing (7/10)22 New Institutional Positions13 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on EBS right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (71%)
Inst. Holders
50 funds
Inst. Value
$289.3M
Inst. Activity
22 buys / 13 sells
Insider Activity
$0.00 buy / $577.2K sell
Insider Net $
-$577.2K
Social Sentiment
43° Neutral
SEC Reports
11
Press Releases
5
Price chart 30d -3.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 other
Aug 10, 2026 SEC INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
Emergent BioSolutions cut its FY2026 revenue guidance to $645-$675 million from $720-$760 million (midpoint down $75M) a
PRESS-RELEASE — Impact 7/10
Jul 24, 2026 Event
GARZULYS
Original Approval — VIAL
Jul 1, 2026 Insider
Williams Paul Anthony sold 3,000 shares
SVP, Products Business @ $8.40 ($25.2K)
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — DOUBLED
1,072,185 shares ($9.0M)
Jun 30, 2026 Inst.
Jun 29, 2026 SEC GOLDMAN SACHS GROUP INC — ADD
1,035,421 shares ($8.7M)
Emergent BioSolutions received a $52.7 million contract modification from the U.S. government (ASPR) for ACAM2000 vaccin
8-K — Impact 5/10
Jun 8, 2026 Insider
Hartzel William surrendered for taxes 1,741 shares
SVP, Bioservices @ $8.00 ($13.9K)
Analyst ratings buy % -14.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
71% rate it Buy or better · 7 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 1 | 4 | 1 | 1 | 0 | 71% | |
| Aug 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Jul 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Jun 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| May 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Apr 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Mar 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Feb 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% |
Price targets
Where 2 covering analysts think EBS trades over the next 12 months.
$11.00 +75.7% upside Strong Buy
Current$6.26 Low$10.00 Median$11.00 High$12.00 2 analysts
$10.00$12.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood -33.3%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
43°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
11 SEC filing reports analyzed · 1 bullish, 2 bearish, 1 mixed, 7 neutral · avg impact 3.7/10.Plus 5 press releases.
BEARISHPRESS-RELEASE7/10
Emergent BioSolutions cut its FY2026 revenue guidance to $645-$675 million from $720-$760 million (m
Aug 10, 2026
BULLISH8-K5/10
Emergent BioSolutions received a $52.7 million contract modification from the U.S. government (ASPR)
Jun 29, 2026
NEUTRALCLUSTER2/10
Three directors of Emergent BioSolutions sold a total of approximately $385K in open-market shares o
May 4, 2026
MIXEDPRESS-RELEASE6/10
Emergent BioSolutions reported Q1 2026 revenue of $156.1M (above the high-end of guidance) but GAAP
Apr 30, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the
Sep 17, 2026
short_volume
Short Volume: EBS — 68.7% short (0.4M / 0.5M)
Short: 371,527 | Exempt: 0 | TRF Vol: 541,090 | Short Ratio: 68.7% | Off-exchange volume (dark pool + OTC)
Sep 16, 2026
short_volume
Short Volume: EBS — 57.2% short (0.4M / 0.6M)
Short: 359,786 | Exempt: 3,840 | TRF Vol: 628,934 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
other
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a ribbon cutting ceremony on Wednesday, September 1
Sep 11, 2026
short_volume
Short Volume: EBS — 60.0% short (0.4M / 0.6M)
Short: 382,130 | Exempt: 2,563 | TRF Vol: 637,104 | Short Ratio: 60.0% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.39 | $-0.41–$-0.37 | -136.9% | -211.8% | 1↑ 0↓ | $0.1B | 2 |
| Next Q | $-0.08 | $-0.11–$-0.05 | 81.6% | -128.3% | 0↑ 1↓ | $0.1B | 2 |
| Current FY | $0.36 | $0.36–$0.36 | -76.5% | -62.1% | 1↑ 0↓ | $0.7B | 2 |
| Next FY | $1.05 | $1.05–$1.05 | 191.0% | — | 1↑ 0↓ | $0.7B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.391 | — |
| 7d ago | $-0.410 | +0.019 |
| 30d ago | $0.350 | -0.741 |
| 60d ago | $0.350 | -0.741 |
| 90d ago | $0.350 | -0.741 |
Institutional ownership
Which big funds own EBS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $289.3M total value (34,527,113 shares) as of 2026-Q2. Top holders: BlackRock,, DIMENSIONAL, STATE. Net buying activity: 22 institutions added/increased vs 13 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 4,716,599 | $39.5M | 13.7% | — |
| DIMENSIONAL FUND ADVISORS LP | 3,076,646 | $25.8M | 8.9% | — |
| STATE STREET CORP | 2,929,238 | $24.6M | 8.5% | — |
| AMERICAN CENTURY COMPANIES INC | 2,770,448 | $23.2M | 8.0% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,198,839 | $18.4M | 6.4% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,337,243 | $11.2M | 3.9% | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,200,791 | $10.1M | 3.5% | — |
| MILLENNIUM MANAGEMENT LLC | 1,072,185 | $9.0M | 3.1% | DOUBLED +101.5% |
| AQR CAPITAL MANAGEMENT LLC | 1,041,151 | $8.7M | 3.0% | DOUBLED +107.0% |
| GOLDMAN SACHS GROUP INC | 1,035,421 | $8.7M | 3.0% | ADD +27.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 532,001 | 1,072,185 | +101.5% | $9.0M |
| GOLDMAN SACHS GROUP INC | ADD | 811,560 | 1,035,421 | +27.6% | $8.7M |
| Russell Investments Group, Ltd. | DOUBLED | 335,898 | 859,482 | +155.9% | $7.2M |
| FEDERATED HERMES, INC. | ADD | 456,319 | 831,125 | +82.1% | $7.0M |
| PRUDENTIAL FINANCIAL INC | ADD | 448,815 | 805,895 | +79.6% | $6.8M |
| MORGAN STANLEY | TRIM | 744,536 | 469,715 | -36.9% | $3.9M |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 648,377 | 353,983 | -45.4% | $3.0M |
| FMR LLC | ADD | 153,888 | 214,169 | +39.2% | $1.8M |
| Squarepoint Ops LLC | TRIM | 299,449 | 148,016 | -50.6% | $1.2M |
| Cetera Investment Advisers | TRIM | 225,483 | 96,301 | -57.3% | $807.0K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
16 insiders, 50 transactions. Net -$577.2K — $0.00 bought, $577.2K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | Williams Paul Anthony | SVP, Products Business | SELL | 3,000 | $8.40 | $25.2K |
| Jun 8, 2026 | Hartzel William | SVP, Bioservices | TAX W/H | 1,741 | $8.00 | $13.9K |
| Jun 8, 2026 | Glessner Coleen | EVP, Quality & Ethics, and CPL | TAX W/H | 2,018 | $8.00 | $16.1K |
| Jun 8, 2026 | LINDAHL RICHARD S | EVP, Chief Financial Officer | TAX W/H | 3,964 | $8.00 | $31.7K |
| Jun 8, 2026 | Williams Paul Anthony | SVP, Products Business | TAX W/H | 694 | $8.00 | $5.6K |
| May 1, 2026 | Zoon Kathryn C | Director | SELL | 1,057 | $8.97 | $9.5K |
| May 1, 2026 | DeGolyer Donald W | Director | SELL | 954 | $8.96 | $8.5K |
| May 1, 2026 | Dayal Sujata Tyagi | Director | SELL | 980 | $8.94 | $8.8K |
| May 1, 2026 | Zoon Kathryn C | Director | SELL | 16,145 | $8.36 | $135.0K |
| May 1, 2026 | DeGolyer Donald W | Director | SELL | 14,527 | $8.36 | $121.4K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for EBS.
Shares short
9,786,380
Settlement Sep 15, 2026
Change vs prior
-9.7%
Semi-monthly cycle
Days to cover
8.6
At avg daily volume
Of shares outstanding
≈19.1%
Estimate — not % of float
All EBS filing & press-release reports (16)
- PRESS-RELEASE reportAug 10, 2026
- 8-K reportJun 29, 2026
- PRESS-RELEASE reportJun 4, 2026
- CLUSTER reportMay 4, 2026
- PRESS-RELEASE reportApr 30, 2026
- PRESS-RELEASE reportApr 29, 2026
- PRESS-RELEASE reportApr 29, 2026
- DEFA14A reportApr 28, 2026
- PRESS-RELEASE reportApr 28, 2026
- DEFA14A reportApr 27, 2026
- PRESS-RELEASE reportApr 16, 2026
- PRESS-RELEASE reportApr 16, 2026
- DEFA14A reportApr 16, 2026
- DEFA14A reportApr 16, 2026
- PRESS-RELEASE reportMar 25, 2026
- DEFA14A reportMar 20, 2026